Latest Period
Q1 2026
Security Snapshot
Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) Institutional Ownership
CUSIP: 687604108
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
183
Shares (Excl. Options)
52,018,172
Price
$49.05
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ORKA on Nasdaq
- Shares outstanding
- 50,314,906
- Price per share
- $68.10
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 52,018,172
- Total reported value
- $2,565,275,674
- % of total 13F portfolios
- 0.01%
- Share change
- -1,040,428
- Value change
- +$48,347,000
- Number of holders
- 183
- Price from insider filings
- $68.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ORKA - Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 687604108.
- 183 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 144 to 183 between Q4 2025 and Q1 2026.
- Reported value moved from $1,602,044,506 to $2,565,275,674.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 183 institutions filings for Q1 2026.
Security key
687604108
Latest holder period
Q1 2026
13F holders
183
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
ORKA full holder history
Oruka Therapeutics, Inc. SEC filings
Oruka Therapeutics, Inc. company facts
Oruka Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 687604108:
Significant Owners of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $670,272,174 | +$122,739,728 | 13,665,080 | +22% | Fairmount Funds Management LLC | 30 Apr 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | -11% | $94,411,973 | +$14,637,703 | 4,909,619 | +18% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 5.3% | -3.3% | $130,801,144 | 2,666,690 | 0% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 | |
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.3% | -18% | $62,382,466 | +$3,409,845 | 2,058,148 | +5.8% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Mar 2026, 183 institutional investors reported holding 52,018,172 shares of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA). This represents 103% of the company’s total 50,314,906 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 7,431,403 | +2.3% | 0.02% | $364,510,318 |
| Venrock Adviser, LLC | 8.2% | 4,148,428 | 0% | 7.6% | $203,480,393 |
| Fairmount Funds Management LLC | 7.4% | 3,705,262 | 0% | 13% | $181,743,101 |
| BlackRock, Inc. | 7% | 3,527,087 | -0.35% | 0% | $173,003,617 |
| VIKING GLOBAL INVESTORS LP | 5.3% | 2,666,690 | 0% | 0.37% | $130,801,145 |
| Paradigm Biocapital Advisors LP | 4.6% | 2,320,316 | +36% | 2.3% | $113,811,500 |
| RTW INVESTMENTS, LP | 4.1% | 2,058,148 | 0% | 1% | $100,952,159 |
| Deep Track Capital, LP | 4% | 2,034,203 | -5.9% | 2.1% | $99,777,657 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 1,859,631 | 0% | 0% | $91,214,901 |
| STATE STREET CORP | 3.2% | 1,613,461 | +17% | 0% | $79,140,262 |
| Remedium Capital Partners, LLC | 3.1% | 1,565,661 | +0.85% | 27% | $76,795,672 |
| PERCEPTIVE ADVISORS LLC | 2.8% | 1,395,501 | -5.5% | 1.4% | $68,449,324 |
| Polar Capital Holdings Plc | 2.1% | 1,047,693 | +7.1% | 0.22% | $51,389,342 |
| CITADEL ADVISORS LLC | 2% | 1,007,537 | +39% | 0.04% | $49,419,690 |
| FRANKLIN RESOURCES INC | 2% | 1,004,056 | +7% | 0.01% | $49,248,948 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 954,867 | +1.3% | 0% | $46,848,119 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.6% | 802,470 | +7.7% | 0.06% | $39,361,154 |
| Avidity Partners Management LP | 1.5% | 760,424 | +15% | 13% | $52,020,606 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 727,449 | +12% | 0% | $35,682,000 |
| Woodline Partners LP | 1.1% | 574,882 | +0.06% | 0.11% | $28,197,962 |
| Cormorant Asset Management, LP | 1.1% | 533,340 | 0% | 1.3% | $26,160,327 |
| Bellevue Group AG | 1% | 507,008 | 0.59% | $24,868,742 | |
| Affinity Asset Advisors, LLC | 0.99% | 499,673 | -38% | 1.4% | $24,508,961 |
| Synergy Asset Management, LLC | 0.95% | 476,196 | +3.8% | 2.5% | $23,357,413 |
| SR One Capital Management, LP | 0.86% | 430,330 | 0% | 2.3% | $21,107,686 |
Institutional Holders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value per share (ORKA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 52,018,172 | $2,565,275,674 | +$48,347,000 | $49.05 | 183 |
| 2025 Q4 | 52,853,967 | $1,602,044,506 | +$170,793,609 | $30.31 | 144 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |